Trial Profile
Afutuzumab in patients with heavily pretreated, indolent non-Hodgkin's lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2011
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary)
- Indications Diffuse large B cell lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors Roche
- 07 Dec 2010 Results were presented at the 52nd Annual Meeting and Exposition of the American Society of Hematology.
- 07 Dec 2010 Results will be reported at ASH 2010, according to a media release.
- 05 Nov 2010 New trial record.